

Acquisition of data:
Carreras-Torres, Brown, Johansson, Wang, Foll, Li,
Rothman, Savage, Gaborieau, McKay, Ye, Henrion, Bruinsma, Jordan,
Severi, Hveem, Vatten, Fletcher, Koppova, Larsson, Wolk, Banks, Selby,
Easton, Pharoah, Andreotti, Beane Freeman, Koutros, Albanes, Mannisto,
Weinstein, Clark, Edwards, Lipworth, Gapstur, Stevens, Carol, Freedman,
Pomerantz, Cho, Kraft, Preston, Wilson, Gaziano, Sesso, Black, Freedman,
Huang, Anema, Kahnoski, Lane, Noyes, Petillo, Colli, Sampson, Besse,
Blanche, Boland, Burdette, Prokhortchouk, Skryabin, Yeager, Mijuskovic,
Ognjanovic, Foretova, Holcatova, Janout, Mates, Mukeriya, Rascu,
Zaridze, Bencko, Cybulski, Fabianova, Jinga, Lissowska, Lubinski,
Navratilova, Rudnai, Szeszenia-Dabrowska, Benhamou, Cancel-Tassin,
Cussenot, Bueno-de-Mesquita, Canzian, Duell, Ljungberg, Sitaram,
Peters, White, Anderson, Johnson, Luo, Buring, Lee, Chow, Moore, Wood,
Eisen, Larkin, Choueiri, Lathrop, Teh, Deleuze, Wu, Houlston, Brennan,
Chanock, Scelo, Purdue.
Analysis and interpretation of data:
Machiela, Hofmann, Carreras-Torres,
Brown, Savage, Scelo, Purdue.
Drafting of the manuscript:
Machiela, Hofmann, Purdue.
Critical revision of the manuscript for important intellectual content:
Machiela, Hofmann, Carreras-Torres, Brown, Savage, Scelo, Purdue.
Statistical analysis:
Machiela, Carreras-Torres.
Obtaining funding:
Brennan, Chanock, Scelo, Purdue.
Administrative, technical, or material support:
None.
Supervision:
Brennan, Chanock, Scelo, Purdue.
Other:
None.
Financial disclosures:
Mark P. Purdue certi
fi
es that all con
fl
icts of
interest, including speci
fi
c
fi
nancial interests and relationships and
af
fi
liations relevant to the subject matter or materials discussed in the
manuscript (eg, employment/af
fi
liation, grants or funding, consul-
tancies, honoraria, stock ownership or options, expert testimony,
royalties, or patents
fi
led, received, or pending), are the following:
None.
Funding/Support and role of the sponsor:
US Department of Health and
Human Services, US National Institute of Health, US National Cancer
Institute, American Cancer Society, Duncan Family Institute for Cancer
Prevention and Risk Assessment, Masaryk Memorial Cancer Institute
were involved in the design and conduct of the study, collection of the
data, and approval of the manuscript. This study was funded by
support from the following institutions: Intramural research program
of the National Cancer Institute, American Cancer Society, Masaryk
Memorial Cancer Institute (MMCI) in Brno was supported by MH CZ -
DRO (MMCI, 00209805). MD Anderson study GWAS was supported in
part by the NIH (grant R01 CA170298) and the Center for Translational
and Public Health Genomics, Duncan Family Institute for Cancer
Prevention and Risk Assessment, The University of Texas MD Anderson
Cancer Center. The WHI program is funded by the National Heart, Lung,
and Blood Institute, National Institutes of Health, US Department of
Health and Human Services through contracts HHSN268201600018C,
HHSN268201600001C, HHSN268201600002C, HHSN268201600003C,
and HHSN268201600004C.
Acknowledgments:
Special thanks to the participants, families, and staff
who made this research possible. The
fi
ndings and conclusions in this
report are those of the author(s) and do not necessarily represent the
views of the National Institutes of Health.
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at
http://dx.doi.org/10.1016/j. eururo.2017.07.015.
References
[1]
Blackburn EH. Structure and function of telomeres. Nature 1991; 350:569 – 73.[2]
Blasco MA. Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet 2005;6:611 – 22.[3]
Hackett JA, Greider CW. Balancing instability: dual roles for telo- merase and telomere dysfunction in tumorigenesis. Oncogene 2002;21:619 – 26.
[4]
Machiela MJ, Hsiung CA, Shu XO, et al. Genetic variants associated with longer telomere length are associated with increased lung cancer risk among never-smoking women in Asia: a report from the female lung cancer consortium in Asia. Int J Cancer 2015;137:311 – 9.
[5]
Machiela MJ, Lan Q, Slager SL, et al. Genetically predicted longer telomere length is associated with increased risk of B-cell lympho- ma subtypes. Hum Mol Genet 2016;25:1663 – 76.
[6]
Zhang C, Doherty JA, Burgess S, et al. Genetic determinants of telomere length and risk of common cancers: a Mendelian ran- domization study. Hum Mol Genet 2015;24:5356 – 66.
[7]
Haycock PC, Burgess S, Nounu A, Zheng J, Okoli GN. Association between telomere length and risk of cancer and non-neoplastic diseases: a Mendelian randomization study. JAMA Oncol 2017;3: 636 – 51.[8]
Wentzensen IM, Mirabello L, Pfeiffer RM, Savage SA. The association of telomere length and cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2011;20:1238 – 50.[9]
Cawthon RM. Telomere length measurement by a novel mono- chrome multiplex quantitative PCR method. Nucleic Acids Res 2009;37:e21.
[10]
Shao L, Wood CG, Zhang D, et al. Telomere dysfunction in peripheral lymphocytes as a potential predisposition factor for renal cancer. J Urol 2007;178:1492 – 6.
[11]
Wu X, Amos CI, Zhu Y, et al. Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst 2003;95:1211 – 8.[12]
Hofmann JN, Baccarelli A, Schwartz K, et al. Risk of renal cell carcinoma in relation to blood telomere length in a population- based case-control study. Br J Cancer 2011;105:1772 – 5.
[13]
Hofmann JN, Lan Q, Cawthon R, et al. A prospective study of leukocyte telomere length and risk of renal cell carcinoma. Cancer Epidemiol Biomarkers Prev 2013;22:997 – 1000.[14]
Weischer M, Nordestgaard BG, Cawthon RM, Freiberg JJ, Tybjaerg- Hansen A, Bojesen SE. Short telomere length, cancer survival, and cancer risk in 47 102 individuals. J Natl Cancer Inst 2013; 105:459 – 68.
[15]
Svenson U, Ljungberg B, Roos G. Telomere length in peripheral blood predicts survival in clear cell renal cell carcinoma. Cancer Res 2009;69:2896 – 901.
[16]
Pal D, Sharma U, Khajuria R, Singh SK, Kakkar N, Prasad R. Augmented telomerase activity, reduced telomere length and the presence of alternative lengthening of telomere in renal cell carcinoma: plausi- ble predictive and diagnostic markers. Gene 2015;562:145 – 51.[17]
Yoshida K, Sakamoto S, Sumi S, Higashi Y, Kitahara S. Telomerase activity in renal cell carcinoma. Cancer 1998;83:760 – 6.[18]
Muezzinler A, Mons U, Dieffenbach AK, et al. Smoking habits and leukocyte telomere length dynamics among older adults: Results from the ESTHER cohort. Exp Gerontol 2015;70:18 – 25.
[19]
Mundstock E, Sarria EE, Zatti H, et al. Effect of obesity on telomere length: Systematic review and meta-analysis. Obesity (Silver Spring) 2015;23:2165 – 74.
[20]
Cunningham JM, Johnson RA, Litzelman K, et al. Telomere length varies by DNA extraction method: implications for epidemiologic research. Cancer Epidemiol Biomarkers Prev 2013;22:2047 – 54.[21]
Hofmann JN, Hutchinson AA, Cawthon R, et al. Telomere length varies by DNA extraction method: implications for epidemiologic research- letter. Cancer Epidemiol Biomarkers Prev 2014;23:1129 – 30.
E U R O P E A N U R O L O GY 7 2 ( 2 0 17 ) 74 7
–
7 5 4
753